Nanobiotix S.A. Stock Price, News & Analysis

Nanobiotix (NASDAQ: NBTX) reported operational progress and cash position for Q1 2021. The company has €107.1 million in cash, significantly up from €28 million in Q1 2020. Despite this, no revenue was generated in Q1 2021, a drop from €24,000 in Q1 2020 due to the end of a collaboration with PharmaEngine. Notable advancements include promising preclinical data for NBTXR3 and the initiation of a phase I trial in esophageal cancer. Collaborations with Sanofi and the retention of IP rights in the Asia-Pacific region were also highlighted.

NANOBIOTIX (NASDAQ: NBTX) announced it will present new data from its oncology pipeline at the 2021 ASCO Annual Meeting from June 4-8. Four abstracts will showcase NBTXR3, a potential first-in-class radioenhancer, across various tumor types and in combination with anti-PD-1 therapies. Key studies include an updated analysis of NBTXR3 in head and neck cancer, with plans for a global phase III trial in 2021. The company will host a virtual investor event on June 11 to discuss these results.

NANOBIOTIX (NASDAQ: NBTX) announced its annual Combined Shareholders Meeting will be held online on April 28, 2021, at 5pm CET with no physical attendance due to COVID-19 measures. Shareholders can vote via postal voting or proxy, with details available in the convene notice published in the Bulletin des Annonces Légales Obligatoires. Written questions must be submitted by April 22, 2021. The meeting format may change according to health regulations. NANOBIOTIX focuses on physics-based cancer treatment innovations and holds numerous patents in nanomedicine.

NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX), a late-stage clinical biotechnology company, announced the filing of its universal registration document and annual report for the fiscal year ended December 31, 2020. These documents, which include the annual financial report and management report, are available on the company's website and the regulatory authorities' sites. Nanobiotix is pioneering physics-based approaches in oncology and has market authorization for its lead product, NBTXR3, in Europe for soft tissue sarcoma. The company is headquartered in Paris and operates subsidiaries in Spain and Germany.

Nanobiotix (NANO, NBTX) reported its fiscal year 2020 results, highlighting stable revenues of €2.5M, primarily from research tax credit and collaboration agreements. Net loss decreased to €33.6M from €50.9M in 2019. R&D expenses fell to €24.3M due to cost-control measures. The company achieved significant milestones, including FDA fast track designation for NBTXR3 in head and neck cancer and progressing towards global phase III trials. Successful IPO raised €93.5M, enhancing financial stability as they aim to advance cancer treatment solutions.

NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX) announced the termination of its License and Collaboration agreement with PharmaEngine, originally established in August 2012. The decision follows disputes over the development strategy of NBTXR3 in the Asia-Pacific region. Nanobiotix retains all rights for NBTXR3, with potential payments to PharmaEngine not exceeding $5 million and royalties on sales for up to 10 years. This shift allows Nanobiotix to explore new opportunities, including evaluating the region for future clinical trials.

NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX), a clinical-stage biotechnology company, announced CEO Laurent Levy's participation in a fireside chat at the H.C. Wainwright Global Life Sciences Conference, scheduled for March 9-10, 2021. The event will feature on-demand sessions and opportunities for one-on-one meetings with investors. NANOBIOTIX focuses on innovative cancer treatments, highlighted by its lead product NBTXR3, a radioenhancer designed to improve radiotherapy efficacy while reducing toxicity. More details, including the corporate presentation, can be found on their website.

NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX) announced promising preclinical findings for its radioenhancer NBTXR3 at the AACR Virtual Special Conference. This unique treatment leverages hafnium oxide nanoparticles to enhance radiotherapy's effects without harming adjacent healthy tissue. The study demonstrated that NBTXR3 combined with anti-PD-1 and immune checkpoint inhibitors significantly improved tumor control and survival in resistant mouse models. The company's approach aims to broaden treatment options across various cancers, suggesting potential advancements in cancer therapy.

NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX) reported a full year 2020 revenue of approximately €50K, down from €68K in 2019. The lack of Q4 revenues was due to a credit note issued after annual adjustments. As of December 31, 2020, cash and cash equivalents totaled €119.2M, bolstered by a successful IPO generating €93.5M in gross proceeds. Key events include the initiation of multiple clinical trials for NBTXR3 and collaboration agreements, including a partnership with Sanofi. The company expects its current funds to support operations through mid-2023.